FDA Broadly Supports Oragenics’ Pre-IND Development Program for Its SARS-CoV-2 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced receipt of feedback to its Type B Pre-IND Meeting Request from the U.S. Food and Drug Administration (FDA) that it is in broad agreement with the company’s […]
Oragenics Signs Process Development and Manufacturing Agreement With Avid Bioservices for Coronavirus Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., and Avid Bioservices, Inc., announced that they have entered into a process development and drug substance manufacturing agreement. Under terms of the agreement, Avid will provide Oragenics with analytical method development, process development and drug substance manufacturing services to support the development of Oragenics’ novel […]
Tiny Florida Medical Research Firm Faces Giant Challenge — COVID-19 Vaccine
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a Tampa-based medical research business with roots in Gainesville, found itself at a crossroads earlier this year right before the COVID-19 pandemic struck America. The company’s previous project had been working on modifying genes related to bacteria in the hopes of stopping oral mucositis in […]
Oragenics Provides Update on SARS-CoV-2 (COVID-19) Program
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, provided an update on progress with its SARS-CoV-2 (COVID-19) vaccine candidate and announced the termination of its clinical development program with AG013 for the treatment of severe oral […]
How to Create a COVID-19 Vaccine
Alan Joslyn Ph.D. president and CEO of UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, speaks with James Di Virgilio, Radio Cade podcast co-host, about COVID-19 vaccine challenges and explore Oragenics journey from idea generation to COVID-19 […]
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced that through its wholly-owned subsidiary, Noachis Terra, it has entered into an agreement with Aragen Bioscience, a leading contract research organization focused on accelerating pre-clinical biologics product […]
After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine
Serendipity is the word Alan Joslyn uses to describe the meeting and eventual acquisition of a Gainesville-based biotech firm. “It’s not every day all of a sudden a private company falls in your lap that’s working in COVID-19,” said Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in […]
Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced its acquisition of UF Innovate | The Hub resident client Noachis Terra Inc., following its entry into a stock purchase agreement, to develop and […]
Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced that early top-line results of the company’s Phase 2 clinical trial of AG013 in oral mucositis in chemoradiation in head and neck cancer patients […]
Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product
Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech alum Oragenics, Inc., a Tampa-based company leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis (OM), talked with Proactive’s Steve Darling at the 12th annual LD Micro Conference. The company is developing the AG013, which […]